OCUGEN, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.395 USD | +8.98% |
|
+12.10% | +141.74% |
| 22/04 | Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating | MT |
| 22/04 | Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating | MT |
Chart calendar Ocugen, Inc.
e8f7fea964999bb2bb74ff2b.9z_DYsD4Lj1tDTQHbwHSgwi_pF0zaDVshP0BD55jMLk.oVWoM4OofWxAZF10GVKfwELz_RhcXXwY8sxXXakLUZTOEocRoahqTl9eRw~8bb12b44e3ccabbb224a9932b5cec192
Upcoming events on Ocugen, Inc.
Past events on Ocugen, Inc.
| 17/04/2024 07:30 pm | Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference |
| 02/04/2024 06:00 pm | Q4 2023 Earnings Call |
| 02/04/2024 05:30 pm | Q4 2023 Earnings Release |
| 09/03/2024 03:15 am | Foundation Fighting Blindness Investing in Cures Summit |
| 01/03/2024 04:35 pm | Abu Dhabi Family Office Summit |
| 27/02/2024 12:15 am | BIO CEO & Investor Conference |
| 21/02/2024 08:30 pm | Clinical Show |
| 07/02/2024 07:30 pm | Pharma Market Research Conference |
| 05/12/2023 12:30 am | Noble Capital Markets Emerging Growth Equity Conference |
| 09/11/2023 07:00 pm | Q3 2023 Earnings Call |
| 09/11/2023 05:00 pm | Q3 2023 Earnings Release |
| 12/10/2023 05:45 am | Cell & Gene Meeting on the Mesa Conference |
| 05/10/2023 08:50 pm | Gene Therapy for Ophthalmic Disorders Conference |
| 03/10/2023 11:00 pm | Chardan Genetic Medicines Conference - Fireside Chat |
| 03/10/2023 06:30 pm | Gene Therapy for Ophthalmic Disorders Conference - Workshop |
| 26/09/2023 10:30 pm | Cantor Global Healthcare Conference |
| 13/09/2023 06:00 pm | OCU400 Phase 1/2 Trial Results Call |
| 22/08/2023 06:00 pm | Q2 2023 Earnings Call |
| 22/08/2023 02:02 am | Q2 2023 Earnings Release |
| 09/06/2023 05:30 pm | Annual General Meeting |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,04 0,01 296.47% | 0,00 0,00 - | 0,00 2,17 - | 6,04 0,00 - | 0,00 |
|
EBITDA | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -14,2 -12,9 -9.77% | -21,3 -15,8 -34.85% | -58,0 -54,2 -6.98% | -84,9 -82,0 -3.55% | -65,5 -72,3 9.33% | -66,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | -58,4 -53,2 -9.86% | -81,4 -81,0 -0.46% | -63,1 -69,0 8.52% | -66,7 |
|
Net income Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | -58,4 -53,1 -9.82% | -81,4 -81,0 -0.46% | -63,1 -69,0 8.52% | -66,7 |
|
EPS USD | Released Forecast Spread | 0,00 0,00 - | -0,31 -0,36 13.89% | -0,30 -0,30 0% | -0,38 -0,38 0% | -0,26 -0,28 8.23% | -0,23 |
| Announcement Date | 27/03/20 | 18/03/21 | 25/02/22 | 28/02/23 | 16/04/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 13,8 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 2,17 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 1,42 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -14,6 -10,8 -35.04% | -18,0 31,4 -157.51% | -19,6 -17,8 -10.02% | -23,1 -22,0 -5.09% | -24,2 -23,8 -1.33% | -17,8 -25,6 30.66% | -23,7 -17,7 -34.45% | -15,4 -18,9 18.35% | -11,5 -15,4 25.01% | |||||
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -14,6 -9,38 -55.52% | -18,0 34,0 -152.97% | -19,5 -17,8 -9.49% | -21,9 -22,0 0.35% | -21,9 -23,8 7.95% | -16,5 -25,6 35.55% | -22,9 -17,3 -32.63% | -14,2 -18,6 24.03% | -11,0 -15,4 28.63% | |||||
|
Net income Million USD | Released Forecast Spread | -14,6 -9,38 -55.52% | -18,0 34,0 -152.97% | -19,5 -17,8 -9.49% | -21,9 -22,0 0.35% | -21,9 -23,8 7.95% | -16,5 -25,1 34.24% | -22,9 -17,3 -32.63% | -14,2 -18,6 24.03% | -11,0 -15,4 28.63% | |||||
|
EPS USD | Released Forecast Spread | -0,07 -0,07 0% | -0,09 0,01 -775.17% | -0,09 -0,08 -18.42% | -0,10 -0,10 -1.7% | -0,10 -0,10 0% | -0,07 -0,11 35.19% | -0,10 -0,07 -37.93% | -0,06 -0,07 14.29% | -0,03 -0,06 50% | -0,06 | -0,07 | -0,06 | -0,07 | |
| Announcement Date | 25/02/22 | 06/05/22 | 05/08/22 | 08/11/22 | 28/02/23 | 05/05/23 | 21/08/23 | 09/11/23 | 16/04/24 | - | - | - | - | - |
| Today 01:35 am | QIAGEN N.V.: Q1 2024 Earnings Release |
| 30/04/2024 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 04:00 pm | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 04:00 pm | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 04:30 pm | ALKERMES PLC: Q1 2024 Earnings Release |
| 02/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Ocugen, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- OCGN Stock
- Calendar Ocugen, Inc.
